To start your customized experience click the start button
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
CURE Communications Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.


Jason M. Broderick
There are now more personalized treatment options for patients with CLL. 
Silas Inman
Arzerra was approved in combination with fludarabine and cyclophosphamide to treat patients with CLL. 
Silas Inman
As new therapies get approved and continue to be investigated, treatment for CLL is rapidly evolving. 
Jason M. Broderick
The FDA expanded the label for Imbruvica for some patients with CLL, as the drug continues to show improved survival benefits. 
Jason M. Broderick
The FDA approved Venclexta for patients with CLL who have a 17p deletion and failed at least one prior therapy.
Andrew J. Roth
The treatment landscape of chronic lymphocytic leukemia is rapidly evolving, according to Jeffrey Jones, an assistant professor at The Ohio State University Comprehensive Cancer Center.
Laura Panjwani
The landscape for treating CLL is changing, bringing about questions and hope for a cure.
Phylis McKiernan, APN, MSN, OCN
Patients taking novel treatments for CLL, and their caregivers, should know which side effects to expect — and recognize when they become emergencies.
Jason M. Broderick
In the phase 3 RESONATE-2 study, Imbruvica improved progression-free survival (PFS) by 84 percent in previously untreated patients with CLL or SLL.
Jason M. Broderick
The approval was based on a near doubling in progression-free survival (PFS) seen with the treatment compared with observation in the phase 3 PROLONG trial.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment


Healthcare Professional

Not Applicable